Emory University, Winship Cancer Institute, School of Medicine, Atlanta, GA 30322, USA.
Expert Opin Investig Drugs. 2011 May;20(5):669-80. doi: 10.1517/13543784.2011.565745. Epub 2011 Mar 28.
Although diffuse large B-cell lymphoma (DLBCL) is commonly considered as a cancer with a high cure rate with conventional therapies recent studies demonstrate that different biological variants of DBLCL exist, and that patients with one DLBCL variant and DLBCL patients who relapse early following rituximab-based therapy have markedly poorer outcomes with conventional management strategies. Over the last decade, there has been an increasing exploration of novel therapies derived from improved understanding of DLBCL biology and tumor-host interactions.
This review examines the biological basis for novel therapeutic approaches in DLBCL and the early clinical data on compounds derived from this research. A description of the expanding options of novel agents and combination therapies for patients with poor risk DLBCL is provided.
Several promising novel agents and novel therapeutic combinations are under development for patients with poor risk DLBCL. Carefully designed clinical trials that build on our improved understanding of DLBCL biology and utilize tissue samples to examine the activity of novel combination therapies should expand treatment options for DLBCL patients in the future.
尽管弥漫性大 B 细胞淋巴瘤（DLBCL）通常被认为是一种通过常规疗法可以获得高治愈率的癌症，但最近的研究表明，DLBCL 存在不同的生物学亚型，而具有一种 DLBCL 亚型的患者以及接受基于利妥昔单抗的治疗后早期复发的 DLBCL 患者，采用常规治疗策略的预后明显较差。在过去十年中，人们越来越多地探索源自对 DLBCL 生物学和肿瘤-宿主相互作用的深入了解的新型疗法。
本综述考察了 DLBCL 中新型治疗方法的生物学基础，以及这些研究衍生的化合物的早期临床数据。描述了针对高危 DLBCL 患者的新型药物和联合治疗方案的扩展选择。
针对高危 DLBCL 患者，有几种有前途的新型药物和新型联合治疗方案正在开发中。未来，精心设计的临床试验应建立在我们对 DLBCL 生物学的深入了解之上，并利用组织样本来评估新型联合治疗方案的活性，从而为 DLBCL 患者扩大治疗选择。
